Abstract：
Recently, the WHO-5 and the ICC 2022 criteria have emphasized poor prognosis in AML/MDS patients with multi-hit TP53 mutations, whereas mutated TP53 plays a critical role in tumorigenesis, drawing substantial interest in exploring its biological behaviors. Diverse characteristics of TP53 mutations, including types, VAF, CNVs, allelic status, karyotypes, and concurrent mutations have been extensively studied. Novel potential targets and comprehensive treatment strategies nowadays are under swift development, owing to great advances in technology. However, accurately predicting prognosis of patients with TP53-mutated myeloid neoplasms remains challenging. And there is still a lack of effective treatment for those patients.
摘要：
最近,WHO-5和ICC2022标准强调了具有多重TP53突变的AML/MDS患者的预后不良，而突变的TP53在肿瘤发生中起着关键作用，对探索其生物学行为产生了极大的兴趣。TP53突变的不同特征，包括类型，VAF,CNVs,等位基因状态，核型,和并发突变已被广泛研究。如今，新的潜在靶点和综合治疗策略正在迅速发展，由于技术的巨大进步。然而,准确预测TP53突变髓系肿瘤患者的预后仍然具有挑战性.对于这些患者仍然缺乏有效的治疗方法。
